The present invention relates to
polyethylene glycol-modified form of
kinin or derivative thereof and pharmaceutical use thereof. In one aspect, by
PEG modification technology, the half-life of the
kinin is greatly prolonged, meanwhile, the
biological activity of the
kinin is exerted, and the problem that pure kinin has extremely short half-life and therefore has no
druggability is solved. PEG modifiers used include, but are not limited to, SPA, SCM and SS modifiers, and can be linear or branched PEG modifiers. In another aspect, the kinin variant has obvious advantages, such as the half-life is further prolonged while the affinity activity with
receptor is maintained, and the
in vivo efficacy of the PEG-modified kinin variant is superior to that of PEG-modified wild-type kinin, so that the
druggability of the kinin is further improved. In addition, the PEG-modified kinin show remarkable
efficacy in various administration routes, especially in
subcutaneous injection and
oral administration, which is convenient in clinical use, and effectively improves the compliance of a patient, and is more suitable for long-term therapeutic administration, such as the convalescent treatment,
relapse prevention and the like of a patient with
cerebral stroke.